Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial looked at people with chronic rhinosinusitis (long-term inflammation of the sinuses and nasal passages). A total of 68 participants took part — 34 received a nasal treatment containing mupirocin (an antibiotic ointment) and 34 received a placebo (a dummy treatment with no active ingredient). By the end of the study, 25 people in the mupirocin group and 33 in the placebo group had completed the trial; 9 people in the mupirocin group and 1 in the placebo group did not finish. The reported data shows that the trial used two questionnaires to measure how participants felt about their sinus-related symptoms. The first was the SNOT-20, a 20-question survey where each question is scored from 1 to 5 (with higher scores meaning worse symptoms), giving a total possible score of 0 to 100. At the end of the study, the mupirocin group reported an average score of 23, while the placebo group reported an average score of 21 — with lower numbers meaning fewer or less bothersome symptoms. The second questionnaire was a Visual Analog Scale (a simple sliding-scale rating) for nasal blockage or congestion, also scored from 0 to 100 where 100 means the worst possible blockage. The reported data shows the mupirocin group scored an average of 24.8 and the placebo group scored an average of 26.4 on this scale. It is worth noting that the trial did not report information about whether these differences between the two groups were considered meaningful by the researchers. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 4 Chronic Rhinosinusitis Trial, Completed
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been diagnosed with chronic rhinosinusitis (long-term inflammation or infection of the sinuses)
- You are scheduled to have endoscopic sinus surgery (a procedure using a small camera to treat the sinuses)
Who may not be able to join:
- You are under 18 years of age
- You have a recorded history of a bad reaction to a medication called mupirocin
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Quality of Life in Chronic Rhinosinusitis Patients
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.